nalbuphine + ropivacaine + lidocaine

This combination drug is an analgesic cocktail administered via thoracic epidural anesthesia (TEA) for the management of severe acute pancreatitis (SAP). Developed and studied by the Affiliated Hospital of Zunyi Medical University, the formulation combines nalbuphine, a mixed opioid agonist-antagonist, with the local anesthetics ropivacaine and lidocaine. Nalbuphine acts as an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors, providing potent analgesia while minimizing common opioid side effects like respiratory depression and pruritus. Ropivacaine and lidocaine function as sodium channel blockers to inhibit nerve conduction. In the context of SAP, this combination is intended not only for pain relief but also to improve pancreatic microcirculation and mitigate the systemic inflammatory response by inhibiting sympathetic nerve activity through epidural blockade.

Other names

nalbuphine + ropivacaine + lidocaine mixturenalbuphine-ropivacaine-lidocaine cocktailnalbuphine + ropivacaine + lidocaine solution